RFK Jr.'s Vaccine Reclassification Gambit Has Global Implications

The Packaging Problem

Robert F. Kennedy Jr. does not need to revoke a vaccine recommendation to undermine it. He only needs to change the words attached to it.

The US health secretary is circulating a request for information asking whether the three-tier system of CDC vaccine recommendations — routine, risk-based, and shared clinical decision-making — should be rewritten. His proposed alternatives sound softer, murkier, and far less authoritative: “recommended with qualification,” “recommended but not during infancy,” or expanded use of the flexible SCDM category, which currently applies to only a handful of vaccines.

The language matters more than most readers will realize. A vaccine labeled “routine” carries the force of a social and medical norm. A vaccine labeled “with qualification” sounds provisional. That shift is not incidental. It is the entire strategy.

Kennedy published his RFI on Monday after weeks of unilateral moves against the CDC’s Advisory Committee on Immunization Practices. He fired its 17 expert members and replaced them with allies who share his skepticism. Last year, under his direction, that reconstituted panel quietly dropped the universal recommendation for a hepatitis B birth dose, drawing condemnation from pediatricians and infectious-disease specialists. A federal judge blocked those changes in March, calling the process likely unlawful.

Now he is trying again, this time wrapping his effort in administrative procedure — a public comment period with a September 20 deadline.

Who Gets to Speak for the American Public?

Kennedy’s RFI frames the question as one about individual autonomy and informed consent. The document asks whether vaccine recommendations should carry a “presumption in favor of individual autonomy and religious freedom.” It also seeks input on how to handle recommendations when randomized controlled trial evidence is absent, infeasible, or unethical — a talking point that has circulated in anti-vaccine circles for years.

The premise is flawed. Large-scale vaccine safety and efficacy are measured through observational studies, post-marketing surveillance, and thousands of peer-reviewed publications. Requiring placebo-controlled trials for every vaccine would halt the development of vaccines for diseases that are already rare, endemic, or ethically unsuitable for trial design. Experts have repeatedly dismissed this argument. Kennedy is advancing it anyway.

What is notable is not the substance of the questions but the audience. The public comment period invites anyone with an opinion to weigh in on technical categories that currently rest on decades of epidemiological evidence. That is where the real danger lies: not in a single policy change but in the erosion of the institutional wall between expert recommendation and political preference.

The Global Ripple

The United States does not dictate global vaccine policy, but it comes close. The World Health Organization’s Strategic Advisory Group of Experts on Immunization monitors national programs worldwide and looks to the CDC’s recommendations as a benchmark for high-income countries. When the US downgrades a vaccine’s standing, other nations take note — especially those with weaker public health infrastructure and less scientific independence.

Low- and middle-income countries often adopt US vaccine schedules as a default. A shift from “routine” to “recommended with qualification” for a vaccine like hepatitis B or meningococcal B would not just confuse American parents. It would feed hesitation in places where health workers already struggle with misinformation, where supply chains are fragile, and where a single doubt can cascade into an outbreak.

The hepatitis B birth-dose reversal is a preview. Denmark, whose schedule Kennedy previously tried to emulate, recommends fewer vaccines than any other high-income country. Its population is small and relatively homogeneous. Copying its approach to a country of 330 million with far more diverse risk profiles is not policy alignment. It is policy surrender.

Who Wins, Who Loses

The winners are clear: anti-vaccine advocates who have long argued that the CDC’s categories are arbitrary, that the science is uncertain, and that parents should be the final arbiters of their children’s medical care. Kennedy’s RFI validates their core claim — that the current system lacks rigor — even though no evidence supports that conclusion.

The losers are the physicians and public health officials who have spent years building trust in vaccination programs. They will now face a political framework that forces them to justify what was once taken for granted. A pediatrician in Ohio and a pediatrician in Nairobi will both feel the fallout when a vaccine that was once routine becomes conditional.

The American Academy of Pediatrics is already suing to block Kennedy’s ACIP changes. But lawsuits move slowly. The RFI’s comment period will play out before any court ruling is final.

What Comes Next

Kennedy has signaled that he wants SCDM recommendations — the flexible, shared-decision category — expanded well beyond its current narrow use. The meningococcal B vaccine is one of the few that currently carries that label. If SCDM becomes the default for vaccines that are now classified as routine, the effect will be to individualize what was once collective. Vaccination shifts from a public health act to a personal choice, and the burden of proof flips: instead of explaining why a vaccine is recommended, providers will need to explain why it might not be.

The Trump administration’s executive order on vaccines, signed two weeks before the RFI, sets the broader direction. Kennedy’s document is the operational detail. Together, they represent the most systematic effort to recalibrate American vaccine policy around ideological preference rather than scientific consensus.

The public has until September 20 to comment. After that, HHS will review responses and decide whether to formalize new categories. If it does, the CDC’s recommendation framework will look different — and sound different — to every American parent and every health ministry abroad that watches Washington for cues.

The categories may seem like bureaucratic details. They are not. Words shape behavior. And the right words, used strategically, can do more damage than any revoked recommendation.